Home » Stocks » PSTX

Poseida Therapeutics, Inc. (PSTX)

Stock Price: $8.63 USD -0.37 (-4.11%)
Updated Jul 23, 2021 4:00 PM EDT - Market closed
Market Cap 536.40M
Revenue (ttm) n/a
Net Income (ttm) -139.30M
Shares Out 61.98M
EPS (ttm) -2.89
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 23
Last Price $8.63
Previous Close $9.00
Change ($) -0.37
Change (%) -4.11%
Day's Open 9.08
Day's Range 8.49 - 9.08
Day's Volume 85,447
52-Week Range 7.63 - 15.79

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

SAN DIEGO, June 2, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create ce...

1 month ago - PRNewsWire

SAN DIEGO, May 11, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create ce...

2 months ago - PRNewsWire

SAN DIEGO, May 11, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create ce...

2 months ago - PRNewsWire

SAN DIEGO, May 6, 2021 /PRNewswire/ --  Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create ce...

2 months ago - PRNewsWire

SAN DIEGO, May 5, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cel...

2 months ago - PRNewsWire

SAN DIEGO, April 27, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. (NASDAQ: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create ...

2 months ago - PRNewsWire

SAN DIEGO, April 8, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create c...

3 months ago - PRNewsWire

SAN DIEGO, March 23, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create ...

4 months ago - PRNewsWire

SAN DIEGO, March 11, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create ...

4 months ago - PRNewsWire

A slew of healthcare stocks is moving on Wednesday in reaction to company-specific catalysts. Sunesis Rises On Hopes of Completion of Merger Deal: Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS), a biophar...

Other stocks mentioned: PRAH, SLRX, SNSS
5 months ago - Benzinga

The biotech reported pipeline progress at its virtual R&D Day.

5 months ago - The Motley Fool

SAN DIEGO, Dec. 5, 2020 /PRNewswire/ -- Poseida Therapeutics, Inc. (NASDAQ:PSTX), a clinical-stage biopharmaceutical company utilizing proprietary gene engineering platform technologies to create cell a...

7 months ago - PRNewsWire

SAN DIEGO, Nov. 2, 2020 /PRNewswire/ -- Poseida Therapeutics, Inc., (Nasdaq: PSTX), a clinical-stage biopharmaceutical company dedicated to utilizing its proprietary gene engineering platform technologi...

8 months ago - PRNewsWire

SAN DIEGO, Sept. 18, 2020 /PRNewswire/ -- Poseida Therapeutics, Inc., (Nasdaq: PSTX), a clinical-stage biopharmaceutical company dedicated to utilizing its proprietary gene engineering platform technolo...

10 months ago - PRNewsWire

SAN DIEGO, Sept. 16, 2020 /PRNewswire/ -- Poseida Therapeutics, Inc.

10 months ago - PRNewsWire

LOS ANGELES--(BUSINESS WIRE)---- $PSTX #PSTX--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Poseida Therapeutics, Inc.

10 months ago - Business Wire

LOS ANGELES--(BUSINESS WIRE)---- $PSTX #PSTX--INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Poseida Therapeutics, Inc.

10 months ago - Business Wire

SAN DIEGO--(BUSINESS WIRE)---- $GNUS #ClassAction--Shareholder rights law firm Robbins LLP is investigating whether Poseida Therapeutics, Inc. (NASDAQ: PSTX) and its officers and directors violated secu...

11 months ago - Business Wire

SAN DIEGO, Aug. 20, 2020 /PRNewswire/ -- Poseida Therapeutics, Inc.

11 months ago - PRNewsWire

NEW YORK, Aug. 19, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Poseida Therapeutics, Inc.

11 months ago - PRNewsWire

Poseida Therapeutics Inc. (NASDAQ: PSTX) stock dropped about 34.5% in the after-hours trading on Monday, after a patient died in a prostate cancer drug trial, according to a filing the company made with...

11 months ago - Benzinga

Poseida Therapeutics Inc. shares dropped in the extended session Monday as the biotech drug maker announced a safety trial for a prostate cancer drug had been halted because of a patient death.

11 months ago - Market Watch

Poseida Therapeutics Inc. PSTX, -0.76% shares were halted in the extended session Monday as the biotech drug maker announced a safety trial for a prostate cancer drug had been halted because of a patien...

11 months ago - Market Watch

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason — they believe the stock price will rise and they want to profit.

Other stocks mentioned: BBBY, AKRO, AZZ, GSK, NKTX, PRSP, TSE ...
1 year ago - Benzinga

Shares of Poseida Therapeutics Inc. PSTX, 0.00% kicked off their public life with a gain, after the biopharmaceutical company's initial public offering priced at the top of the expected range, but those...

1 year ago - Market Watch

About PSTX

Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company is developing P-BCMA-101, an autologous chimeric antigen receptor T cell (CAR-T) targeting B cell maturation antigen that is in Phase II clinical trial; P-PSMA-101, an autologous CAR-T product candidate for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC) is in Phase I clinical trials; P-BCMA-ALLO1, an allogeneic CAR-T product candidate to treat rel... [Read more...]

Industry
Biotechnology
IPO Date
Jul 10, 2020
CEO
Eric Ostertag
Employees
208
Stock Exchange
NASDAQ
Ticker Symbol
PSTX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for PSTX stock is "Strong Buy." The 12-month stock price forecast is 25.67, which is an increase of 197.45% from the latest price.

Price Target
$25.67
(197.45% upside)
Analyst Consensus: Strong Buy